Patient characteristics and 5-y EFS of children and adolescents with newly diagnosed Ph− B-ALL treated on DFCI ALL 05-001
| . | N (%) . | 5-y EFS (95% CI), % . | P . |
|---|---|---|---|
| Overall | 678 | 87 (84-89) | |
| Initial DFCI risk group | <.001 | ||
| Standard | 460 (68) | 91 (88-94) | |
| High | 218 (32) | 77 (71-82) | |
| Age at diagnosis, y | .002* | ||
| <10 | 531 (78) | 89 (86-91) | |
| ≥10 | 147 (22) | 79 (71-85) | |
| 10-<15 | 97 (14) | 85 (76-91) | |
| ≥15 | 50 (7) | 66 (51-78) | |
| WBC at diagnosis, × 109/L | <.001 | ||
| <50 | 578 (85) | 90 (87-92) | |
| ≥50 | 100 (15) | 70 (60-78) | |
| Sex | .51 | ||
| Male | 357 (53) | 86 (82-89) | |
| Female | 321 (47) | 87 (83-91) | |
| CNS status at diagnosis | .50 | ||
| CNS-1 | 540 (80) | 87 (84-90) | |
| CNS-2 | 90 (13) | 86 (77-92) | |
| CNS-3 | 6 (1) | 100 (-) | |
| Traumatic with blasts | 24 (3) | 75 (53-88) | |
| Traumatic without blasts | 18 (3) | 89 (62-97) | |
| Down syndrome | 25 (4) | 95 (68-99) | .19 |
| Cytogenetics | |||
| Hyperdiploidy (51-65 chr) | 198 (29) | 89 (84-93) | .11 |
| Trisomy chr 4 and 10 | 121 (18) | 92 (86-96) | .034 |
| No double trisomy | 77 (11) | 85 (74-91) | .74 |
| ETV6-RUNX1 | 154 (23) | 95 (90-98) | <.001 |
| Hypodiploidy (<45 chr) | 10 (1) | 80 (41-95) | .50 |
| KMT2A-rearranged | 12 (2) | 58 (27-80) | .001 |
| iAMP21 | 13 (2) | 67 (33-86) | .081 |
| TCF3-PBX1 | 23 (3) | 82 (59-93) | .39 |
| Normal karyotype | 128 (19) | 87 (79-92) | .54 |
| Final DFCI risk group† | <.001 | ||
| Standard | 407 (60) | 94 (91-96) | |
| High | 176 (26) | 84 (77-88) | |
| Very high | 65 (10) | 79 (67-87) | |
| End-induction (day 32) MRD† | <.001 | ||
| Low <10−3 | l488 | 91 (88-93) | |
| High ≥10−3 | 47 | 77 (62-87) | |
| Indeterminate/unknown‡ | 113 | 87 (78-92) |
| . | N (%) . | 5-y EFS (95% CI), % . | P . |
|---|---|---|---|
| Overall | 678 | 87 (84-89) | |
| Initial DFCI risk group | <.001 | ||
| Standard | 460 (68) | 91 (88-94) | |
| High | 218 (32) | 77 (71-82) | |
| Age at diagnosis, y | .002* | ||
| <10 | 531 (78) | 89 (86-91) | |
| ≥10 | 147 (22) | 79 (71-85) | |
| 10-<15 | 97 (14) | 85 (76-91) | |
| ≥15 | 50 (7) | 66 (51-78) | |
| WBC at diagnosis, × 109/L | <.001 | ||
| <50 | 578 (85) | 90 (87-92) | |
| ≥50 | 100 (15) | 70 (60-78) | |
| Sex | .51 | ||
| Male | 357 (53) | 86 (82-89) | |
| Female | 321 (47) | 87 (83-91) | |
| CNS status at diagnosis | .50 | ||
| CNS-1 | 540 (80) | 87 (84-90) | |
| CNS-2 | 90 (13) | 86 (77-92) | |
| CNS-3 | 6 (1) | 100 (-) | |
| Traumatic with blasts | 24 (3) | 75 (53-88) | |
| Traumatic without blasts | 18 (3) | 89 (62-97) | |
| Down syndrome | 25 (4) | 95 (68-99) | .19 |
| Cytogenetics | |||
| Hyperdiploidy (51-65 chr) | 198 (29) | 89 (84-93) | .11 |
| Trisomy chr 4 and 10 | 121 (18) | 92 (86-96) | .034 |
| No double trisomy | 77 (11) | 85 (74-91) | .74 |
| ETV6-RUNX1 | 154 (23) | 95 (90-98) | <.001 |
| Hypodiploidy (<45 chr) | 10 (1) | 80 (41-95) | .50 |
| KMT2A-rearranged | 12 (2) | 58 (27-80) | .001 |
| iAMP21 | 13 (2) | 67 (33-86) | .081 |
| TCF3-PBX1 | 23 (3) | 82 (59-93) | .39 |
| Normal karyotype | 128 (19) | 87 (79-92) | .54 |
| Final DFCI risk group† | <.001 | ||
| Standard | 407 (60) | 94 (91-96) | |
| High | 176 (26) | 84 (77-88) | |
| Very high | 65 (10) | 79 (67-87) | |
| End-induction (day 32) MRD† | <.001 | ||
| Low <10−3 | l488 | 91 (88-93) | |
| High ≥10−3 | 47 | 77 (62-87) | |
| Indeterminate/unknown‡ | 113 | 87 (78-92) |
Chr, chromosome.
P value reflects age with grouping of <10 and ≥10 y. For age grouping of <10, 10-<15, and ≥15 y, P < .001.
DFS reported for 648 patients with final DFCI risk group and MRD subgroups.
Characteristics of patients with indeterminate/unknown end-induction MRD: 72% <10 y of age at diagnosis, 57% male, 89% with WBC at diagnosis <50 × 109/L.